SecBot SecBot
6-K ·Filed Aug 31, 2026

DRTS

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizonmonths Processed2mo ago SEC0001213900-26-095370
Notable filing: 6-K
Actionable Insight ▲ Bullish

Enrollment completion with strong demand signals high investigator and patient interest, reducing clinical risk. Monitor for early 2027 data readout and any financing updates for the pivotal study. The rapid enrollment may accelerate timelines and increase partnership interest.

DirectionBullish
Confidencehigh
Horizonmonths

Alpha DaRT

▲ Bullish Named in this 6-K
Impact
Phase
Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
Time to market
The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
Next catalyst
None dated

What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$14.11
T+0 close · Aug 31, 2026 · via day close
Latest settled
+7.65%
T+20 · $15.19 · next T+60 in 7d
Vs SPY
+7.84%
α at T+20
Latest observation
+10.09%
T+52 · FF3 residual α
  1. T+0 · Aug 31 $14.11entry
  2. T+1 · 3mo ago −1.06%α −0.38% · $13.96
  3. T+5 · 2mo ago +5.17%α +5.32% · $14.84
  4. T+20 · 7w ago +7.65%α +7.84% · $15.19
  5. T+54 · todayOpen
  6. T+60 · in 7d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau completed enrollment in its IMPACT pilot study of Alpha DaRT for pancreatic cancer, enrolling 48 patients (4x the original 12) after three expansions driven by strong demand. This de-risks the pancreatic program and supports the design of a planned pivotal study, with initial data expected in early 2027. The filing is a positive clinical milestone for a pre-commercialization company with a $1.4B market cap and strong analyst consensus.

Key Facts

  • IMPACT study enrolled 48 patients, expanded three times from original 12-patient design
  • Study conducted under U.S. IDE across 10 centers in US, Canada, and Israel
  • Alpha DaRT delivered as one-time add-on to first-line chemotherapy (mFOLFIRINOX or gemcitabine + nab-paclitaxel)
  • Initial data targeted for early 2027 to inform pivotal study design
  • Global pancreatic program includes ACAPELLA trial in France and University of Verona study
  • Pancreatic cancer is third leading cause of cancer death in US with ~66,000 new cases/year

Financial Impact

No financial data in filing; milestone de-risks pipeline for a pre-revenue company with $1.4B market cap

Risk Factors

  • Pilot study only; no efficacy data yet, results may not support pivotal design
  • Alpha DaRT not approved for any indication; regulatory path uncertain
  • Company likely needs additional capital to fund pivotal study and operations

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-095370
Document: ea0303693-6k_alpha.htm0001213900-26-095370
Document: 0001213900-26-095370-index-headers.html0001213900-26-095370
Document: 0001213900-26-095370-index.html0001213900-26-095370
Document: 0001213900-26-095370.txt0001213900-26-095370

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 31, 2026